Status:

UNKNOWN

Online Cognitive Rehabilitation of Executive Dysfunction in Nonamnestic MCI

Lead Sponsor:

Baycrest

Collaborating Sponsors:

Centre for Aging and Brain Health Innovation

Conditions:

Nonamnestic Mild Cognitive Impairment

Cognitive Dysfunction

Eligibility:

All Genders

65+ years

Phase:

NA

Brief Summary

Nonamnestic mild cognitive impairment (naMCI) is a prodromal state characterized by deficits in executive functioning, a collection of higher-order abilities involved in organization, planning, inhibi...

Eligibility Criteria

Inclusion

  • Diagnosis of nonamnestic mild cognitive impairment
  • Available to participate in all testing and intervention sessions
  • Access to a computer
  • Computer familiarity
  • Normal or corrected-to-normal vision and hearing

Exclusion

  • Diagnosis of amnestic mild cognitive impairment or dementia
  • Moderate to severe affective impairment defined by score above cut-off for depression on the Patient Health Questionnaire-9 (PHQ-9; Kroenke et al., 2001)

Key Trial Info

Start Date :

August 20 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 30 2021

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT04503798

Start Date

August 20 2020

End Date

December 30 2021

Last Update

August 7 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Baycrest Health Sciences

Toronto, Ontario, Canada, M6A2E1